Hemogenyx Pharmaceuticals Plc (HOPHF)
Sector: Biotechnology
Industry: Biotechnology
Hemogenyx Pharmaceuticals Plc
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Nov 9, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Nov 6, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Nov 3, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Nov 2, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 30, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 29, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 26, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 23, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 22, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 19, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 16, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 15, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 12, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 9, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
| Oct 6, 2026 | 2.33 | 2.33 | 2.33 | 2.33 | 25,000 |
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases.
The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments.
Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies.
Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.
based on 6.90M shares outstanding
30d Avg
25.00K
60d Avg
25.00K
90d Avg
25.00K